A wave of state-level legislative and regulatory action is bearing down on the hemp-derived cannabinoid market. From Delaware to Virginia, lawmakers and regulators are advancing measures that would impose strict THC thresholds, tighten product classifications, and add licensing requirements that could fundamentally alter which products remain legally sellable - and through which retail channels. The proposals, tracked through late May 2026, reflect a broader reckoning with the gap between federal hemp law and what has become a sprawling, loosely regulated market in intoxicating hemp-derived products.
The 0.4 Milligram Threshold and What It Actually Means for Retailers
The number showing up repeatedly in these proposals - 0.4 milligrams of total THC per container - is not a packaging adjustment. It is, in practical terms, a near-total prohibition on the hemp-derived cannabinoid products that currently occupy shelf space in convenience stores, smoke shops, wellness boutiques, and online marketplaces.
Delaware's HB 395, which has cleared committee, would apply that 0.4 mg per-container ceiling to hemp-derived products that would otherwise be treated as marijuana. Products exceeding it could only be sold through Delaware's licensed cannabis dispensary system. The bill would also prohibit cannabinoids not naturally produced by the cannabis plant - or artificially synthesized outside it - if intended for human or animal consumption. By the bill's own logic, products containing those ingredients would have no legal retail pathway in the state at all.
Illinois HB5784 goes the same direction. Its 0.4 mg per-container cap covers not just THC but other cannabinoids deemed to have similar intoxicating effects - a definitional scope that matters enormously for SKU management. Any product exceeding the threshold would be reclassified and restricted to licensed cannabis dispensary sales. The bill also proposes extensive registration and compliance requirements for both manufacturers and retailers, along with broad enforcement authority. For multi-state operators or brands that currently move hemp-derived products through general retail, the Illinois proposal would require a fundamental rethink of distribution strategy.
Philadelphia's Bill No. 260163 takes a parallel approach at the municipal level. The City Council is considering a framework for what the ordinance calls "intoxicating substances," which encompasses hemp-derived cannabinoid products. The 0.4 mg per-container threshold appears here as well, alongside a specific set of operational requirements:
- Sales restricted to adults 21 years of age or older
- A new "Intoxicating Substance Retailer" license required for each retail location
- Zoning and location restrictions on retailers
- Mandatory testing for THC concentration, contaminants, heavy metals, pesticides, solvents, mycotoxins, and microbial impurities
- Labeling requirements and civil penalties for violations
- Prohibition on cannabinoids not naturally produced by the cannabis plant
That testing mandate is worth pausing on. Requiring COA-backed verification for heavy metals, pesticides, mycotoxins, and microbial impurities brings hemp-derived product safety standards closer to those applied in licensed cannabis markets - a shift that would materially increase compliance costs for smaller manufacturers who have not built that infrastructure.
Nebraska and New Jersey: Divergent Approaches, Same Underlying Pressure
Nebraska is moving through a different regulatory mechanism. The state Department of Agriculture has issued a Notice of Rulemaking Hearing under the Nebraska Pure Food Act, proposing "Adulterated Food Product Regulations" that could classify products containing tetrahydrocannabinols - including gummies, drops, and beverages - as adulterated or misbranded food. A rulemaking hearing is scheduled for June 18, 2026. Nebraska using food safety law rather than cannabis-specific legislation to address hemp-derived THC products is a notable approach; it sidesteps the cannabis classification debate entirely and frames the issue as a consumer protection and food integrity matter.
New Jersey's situation is more nuanced. The state already runs one of the more restrictive hemp frameworks in the country, and the pending legislation - A5051, which has passed the House, and companion bill S4297 in the Senate - is largely about adjusting an existing system rather than building a new one. The proposals would extend certain implementation deadlines from May 31, 2026, to November 13, 2026, giving processors and retailers more time to come into compliance. On intoxicating hemp beverages specifically, the legislation would allow cans containing up to 5 milligrams of THC per serving and 10 milligrams per container, as well as resealable 750 mL bottles with up to 40 servings of 5 milligrams each - 200 milligrams total THC per bottle. That bottle format is a meaningful concession to the beverage market.
The New Jersey bill would also allow intoxicating hemp beverages to be displayed in customer-accessible areas - rather than stored behind a counter - under specific monitoring, signage, and age-verification conditions. A 10 percent laboratory testing variance for cannabinoid concentrations would also be permitted, which matters practically for brands managing product consistency across batches. Certain alcohol license holders would gain expanded ability to sell these beverages for off-premises consumption. The non-beverage hemp cannabinoid market, however, would remain tightly restricted under existing state rules.
Virginia's Veto and What It Signals About Hemp Policy Spillover
Virginia Governor Abigail Spanberger's veto of SB 542/HB 642 - legislation that would have established a regulated adult-use marijuana retail marketplace - was not directly a hemp policy decision. But it has hemp policy implications. The U.S. Hemp Roundtable, through General Counsel Jonathan Miller, publicly stated that the organization had asked Governor Spanberger to veto the bill because it would have imposed new restrictions on legal hemp products. The veto was granted, with the Governor citing public safety, impaired driving, youth access, and implementation concerns.
The takeaway for the hemp industry isn't that Virginia is a safe harbor - it's that hemp regulatory questions remain live in the Commonwealth and are likely to resurface in future legislative sessions. When a state's adult-use cannabis framework and its hemp regulations become entangled in the same political debate, the outcomes are unpredictable for operators on both sides.
What Operators and Brands Should Be Tracking Now
The convergence of these proposals points to a trend that has been building for some time: state regulators and legislators are no longer willing to let the hemp-derived cannabinoid market operate in the ambiguity created by the 2018 Farm Bill's definition of hemp. The 0.4 mg per-container threshold appearing across Delaware, Illinois, and Philadelphia is not a coincidence - it reflects a policy consensus forming around the idea that intoxicating hemp products belong in the same regulatory channel as licensed cannabis, not in general retail.
For hemp brands and distributors currently relying on broad retail access - gas stations, health stores, online direct-to-consumer - the compliance exposure is real and near-term. Reclassification into cannabis dispensary channels means contending with state license requirements, seed-to-sale tracking systems, wholesale pricing compression, and the cost of lab testing that meets licensed-market standards. For dispensary operators, it potentially means new competition - and new inventory categories - arriving with their own compliance histories and brand identities already established in the general market.
The thing is, not all of these proposals will pass in their current form. Legislative timelines shift, industry lobbying is active, and some bills will be amended substantially before any vote. But the directional pressure is clear. Operators building product lines, retail strategies, or distribution agreements around hemp-derived cannabinoids should be stress-testing those plans against a near-future in which 0.4 mg per container is the ceiling - not a proposal, but the law.
